KRAS and metastatic neoplasm: Newer models that express cancer-initiating oncogenes, such as KRAS and its downstream effector c-MYC in a ligand-controlled manner, provided additional insight into the significance of these oncogenic drivers in premalignant lesions as well as primary and metastatic tumors in vivo.